Silexion Therapeutics Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.1M
- Price
- $0.3858
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.31%
- Volume
- 95.2K
About
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Quick stats
Shares outstanding1.3M
Computed float1.1M
Float / shares81.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002022416
Websitehttps://silexion.com
AI Summary
AI-generated1/15
majormixedearnings
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Silexion advanced its lead asset SIL204 into an active Phase 2/3 clinical program for locally advanced pancreatic cancer, initiating the trial at Tel Aviv Sourasky Medical Center following regulatory approvals in Israel and Germany.
To support the program and restore Nasdaq compliance, the company executed a 1-for-10 reverse stock split and closed a public offering raising approximately $2.5 million in gross proceeds.
Financial results for the second quarter showed a net loss of $3.6 million, driven by a 120% increase in R&D expenses to $2.2 million as the company prepared for clinical execution.
Red flags
- Reverse stock split (1-for-10) executed to maintain listing compliance
- Substantial doubt about ability to continue as a going concern disclosed in financial statements
- Cash balance of $2.2M as of June 30, 2026 is low relative to quarterly operating expenses (~$3.7M)